Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K. Denton is active.

Publication


Featured researches published by K. Denton.


Journal of Endourology | 2008

Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma.

Steve K. Williams; K. Denton; Andrea Minervini; Jon Oxley; Jay Khastigir; Anthony G. Timoney; Francis X. Keeley

PURPOSE To determine the accuracy of radiographic studies, ureteroscopy, biopsy, and cytology in predicting the histopathology of upper-tract transitional cell carcinoma (TCC). MATERIALS AND METHODS From 1998 to 2006, 46 upper-tract lesions were diagnosed ureteroscopically and underwent nephroureterectomy, and 30 of them were subjected to direct ureteroscopic inspection and biopsy. Fresh samples were delivered to the cytopathology laboratory and histology samples were prepared whenever visible tissue was present. Radiological, ureteroscopic, cytology, and biopsy data were compared to the actual grades and stages of these 30 surgical specimens. RESULTS Retrograde ureteropyelography was suggestive of malignancy in 29 of 30 cases, but did not predict the grade or stage accurately. Cytology was positive for malignancy in 21 of 30 cases (70%). Grading of ureteroscopic specimens was possible in all cases. At nephroureterectomy two cases were found to have no tumor (T(0)). Of the remaining 28 cases, the biopsy grade proved to be identical in 21 (75%). Grade 1 or 2 ureteroscopic specimens had a low-stage (T(0), T(a), or T(1)) tumor in 17 of 25 (68%); in contrast, 3 of 5 (60%) high-grade specimens had invasive tumor (T(2) or T(3)). For patients with grade 2 ureteroscopic specimens, combining exfoliated cell cytology and biopsy grade improved the accuracy in predicting high-stage and high-grade disease. CONCLUSIONS This study confirms previous findings that ureteroscopic inspection and biopsy provides accurate information regarding the grade and stage of upper-tract TCC. Combining exfoliated cell cytology improves the predictive power of biopsy grade 2 disease for high-risk specimen grade and stage. Our data suggest that ureteroscopic findings may predict muscle invasion.


BMJ | 2007

Liquid based cytology in cervical cancer screening

K. Denton

Is as sensitive as conventional cytology, and has other advantages


Cytopathology | 2008

The revised BSCC terminology for abnormal cervical cytology

K. Denton

The BSCC terminology was originally published in 1986 and although highly successful, requires revision. Through a process of professional consensus and literature review this has been undertaken by the BSCC. The revision takes account of recent developments and improvements in understanding of morphology and disease process and is compatible with other terminologies in use elsewhere, whilst still maintaining a focus on practice in the UK cervical screening programmes.


Cytopathology | 2009

BSCC Code of Practice--fine needle aspiration cytology.

Gabrijela Kocjan; Ashish Chandra; P. Cross; K. Denton; T. Giles; Amanda Herbert; P. A. Smith; D. Remedios; Philip Wilson

The British Society for Clinical Cytology Code of Practice on fine needle aspiration cytology complements that on exfoliative cytopathology, which was published in the last issue (Cytopathology 2009;20:211–23). Both have been prepared with wide consultation within and outside the BSCC and have been endorsed by the Royal College of Pathologists. A separate code of practice for gynaecological cytopathology is in preparation. Fine needle aspiration (FNA) cytology is an accepted first line investigation for mass lesions, which may be targeted by palpation or a variety of imaging methods. Although FNA cytology has been shown to be a cost‐effective, reliable technique its accurate interpretation depends on obtaining adequately cellular samples prepared to a high standard. Its accuracy and cost‐effectiveness can be seriously compromised by inadequate samples. Although cytopathologists, radiologists, nurses or clinicians may take FNAs, they must be adequately trained, experienced and subject to regular audit. The best results are obtained when a pathologist or an experienced and trained biomedical scientist (cytotechnologist) provides immediate on‐site assessment of sample adequacy whether or not the FNA requires image‐guidance. This COP provides evidence‐based recommendations for setting up FNA services, managing the patients, taking the samples, preparing the slides, collecting material for ancillary tests, providing rapid on‐site assessment, classifying the diagnosis and providing a final report. Costs, cost‐effectiveness and rare complications are taken into account as well as the time and resources required for quality control, audit and correlation of cytology with histology and outcome. Laboratories are expected to have an effective quality management system conforming to the requirements of a recognised accreditation scheme such as Clinical Pathology Accreditation (UK) Ltd.


Cytopathology | 2009

The BSCC Code of Practice - exfoliative cytopathology (excluding gynaecological cytopathology)

Ashish Chandra; P. Cross; K. Denton; T. Giles; D. Hemming; C. Payne; A. Wilson; Philip Wilson

Exfoliative cytopathology (often referred to as non‐gynaecological cytology) is an important part of the workload of all diagnostic pathology departments. It clearly has a role in the diagnosis of neoplastic disease but its role in establishing non‐neoplastic diagnoses should also be recognised. Ancillary tests may be required to establish a definitive diagnosis. Clinical and scientific teamwork is essential to establish an effective cytology service and staffing levels should be sufficient to support preparation, prescreening, on‐site adequacy assessment and reporting of samples as appropriate. Routine clinical audit and histology/cytology correlation should be in place as quality control of a cytology service. Cytology staff should be involved in multidisciplinary meetings and appropriate professional networks. Laboratories should have an effective quality management system conforming to the requirements of a recognised accreditation scheme such as Clinical Pathology Accreditation (UK) Ltd. Consultant pathologists should sign out the majority of exfoliative cytology cases. Where specimens are reported by experienced biomedical scientists (BMS), referred to as cytotechnologists outside the UK, this must only be when adequate training has been given and be defined in agreed written local protocols. An educational basis for formalising the role of the BMS in exfoliative cytopathology is provided by the Diploma of Expert Practice in Non‐gynaecological Cytology offered by the Institute of Biomedical Science (IBMS). The reliability of cytological diagnoses is dependent on the quality of the specimen provided and the quality of the preparations produced. The laboratory should provide feedback and written guidance on specimen procurement. Specimen processing should be by appropriately trained, competent staff with appropriate quality control. Microscopic examination of preparations by BMS should be encouraged wherever possible. Specific guidance is provided on the clinical role, specimen procurement, preparation and suitable staining techniques for urine, sputum, semen, serous cavity effusion, cerebrospinal fluid, synovial fluid, cyst aspirates, endoscopic specimens, and skin and mucosal scrapes.


Journal of Endourology | 2008

Ureteroscopic Management of Upper-Tract Urothelial Cancer : An Exciting Nephron-Sparing Option or an Unacceptable Risk?

Daniel Painter; K. Denton; Anthony G. Timoney; Francis X. Keeley

PURPOSE To discuss the merits of the endoscopic management of upper-tract transitional-cell carcinoma (UTTCC). We present original data from our institution over an 8-year period and a review of some of the world literature. A discussion of the overall suitability of this modality for both clinician and patient is presented. PATIENTS AND METHODS A retrospective chart review was performed comprising operative logs, departmental databases, and pathologic registers. These sources were analyzed, and data were collected on all patients who underwent ureteroscopic treatment of UTTCC. Patients with at least 6 months of follow-up were included in the study. RESULTS Forty-five patients (mean age 65 yrs) were identified who had undergone ureteroscopic treatment for UTTCC with either therapeutic or palliative intent between 1998 and 2006. Of these, 19 procedures were performed electively in patients with normal contralateral kidneys. Those patients with low-volume, low-grade tumors on biopsy and negative results of urinary cytologic evaluation recovered well, with few recurrences. None of this group progressed to radical surgery. Of 12 patients never considered for radical surgery, only 1 died of the disease after a median follow-up of 15 months. CONCLUSION Elective ureteroscopic holmium:yttrium-aluminum-garnet laser ablation of UTTCC is a safe and effective treatment for a select group of patients. In our institution, patients with normal functioning contralateral kidneys are considered for endoscopic treatment and follow-up of their disease if disease is found to be of low grade and volume. Inadequacies in the staging of UTTCC mean that this may, in some cases, turn out to be suboptimal management, and therefore we maintain a low threshold for recommending radical surgery. For another group of patients with single kidneys, global renal dysfunction, or severe comorbidity, endoscopic treatment can prove a valuable palliative option even in those persons who have a large tumor bulk or relatively rapid disease recurrence.


BJUI | 2007

The modern management of upper urinary tract urothelial cancer: tumour diagnosis, grading and staging

Daniel J. Painter; A.G. Timoney; K. Denton; Peter Alken; Francis X. Keeley

Three of the four mini‐reviews this month deal with the topic of upper tract urothelial cancer, intending to cover completely the issues of diagnosis, staging and grading, as well as surgical treatment, both open and laparoscopic. In this way the reader should be able to have at hand most of the relevant important information about the subject, all in one issue.


Cytopathology | 2014

The role of cytological follow‐up after radical vaginal trachelectomy for early‐stage cervical cancer

K. Edey; K. Denton; J. Murdoch

To identify whether recurrences were picked up by cytology alone after radical vaginal trachelectomy and to determine the false‐positive rate of abnormal cytology.


Cytopathology | 2008

Bland dyskaryosis: a new pitfall in liquid-based cytology.

K. Denton; D. N. Rana; M. A. Lynch; Mina Desai

Objective:  To describe our experience in recognizing an unusual presentation of severe dyskaryosis at two large cytology centres using ThinPrep liquid‐based cytology (LBC). LBC has been introduced in England following successful pilot studies. It is clear that LBC improves visualization and preservation of cells, and that sensitivity for high‐grade dyskaryosis is at least as good as for conventional cytology, and may be better. Several variants of high‐grade dyskaryosis have been described on conventional cytology, including small and pale cell dyskaryosis. These are also seen on LBC.


Cytopathology | 1999

Training in cervical cytology, past, present and future

K. Denton

In recent years every aspect of the practice of cytology has come under close scrutiny. It is perhaps surprising therefore that very little has been published on the subject of training in cytology. Whilst training is an issue in all aspects of diagnostic cytology, this review will concentrate on cervical cytology.

Collaboration


Dive into the K. Denton's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ashish Chandra

Guy's and St Thomas' NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

D. N. Rana

Manchester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar

M. A. Lynch

Manchester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

T. Giles

Royal Liverpool University Hospital

View shared research outputs
Top Co-Authors

Avatar

Francis X. Keeley

Thomas Jefferson University

View shared research outputs
Top Co-Authors

Avatar

Mina Desai

Los Angeles Biomedical Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge